• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

    84.20 +2.72 (+3.33%)
    Streaming Delayed Price Updated: 1:03 PM EST, Jan 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,757,934
    Open 82.50
    Bid (Size) 84.15 (200)
    Ask (Size) 84.26 (600)
    Prev. Close 81.49
    Today's Range 82.40 - 86.15
    52wk Range 23.95 - 83.61
    Shares Outstanding 141,797,854
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +5.7%
    +5.7%
    1 Month
    +3.3%
    +3.3%
    3 Month
    +22.1%
    +22.1%
    6 Month
    +103.7%
    +103.7%
    1 Year
    +146.9%
    +146.9%

    More News

    Read More
    News headline image
    The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
    Via PredictStreet
    Topics Economy Intellectual Property Stocks
    News headline image
    Earnings Scheduled For October 29, 2025 ↗
    Via Benzinga
    News headline image
    Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen Completes Acquisition of Alcyone Therapeutics
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present at upcoming investor conferences
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗
    Via Benzinga
    News headline image
    Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗
    Via Investor's Business Daily
    Topics Death
    News headline image
    Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗
    Via Benzinga
    News headline image
    Ionis (IONS) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗
    Via Investor's Business Daily
    News headline image
    Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday ↗
    Via Benzinga
    News headline image
    Ionis reports third quarter 2025 financial results and highlights progress on key programs
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
    Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
    What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
    The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 84.20
    When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 01/07/26 01:03 PM ET
    What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 11.94B
    How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
    Ionis Pharmaceuticals, Inc. - Common Stock has 12B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.